The Official Journal of EuroPCR and the European Association of Percutaneous Coronary Interventions (EAPCI)

Editorial

Antithrombotic therapy after TAVI: where are we going?

EuroIntervention 2019;15:563-565. DOI: 10.4244/EIJV15I7A102

1. Department of Cardiology, Rigshospitalet, University of Copenhagen, Copenhagen, Denmark


Surgical bioprosthetic aortic valves were introduced with the purpose of avoiding oral anticoagulation (OAC) therapy and thereby the risk of major bleeding in elderly patients. During the last decade, transcatheter bioprosthetic aortic valves have become an alternative to surgical aortic valve replacement (SAVR), and antithrombotic therapy after transcatheter aortic valve implantation (TAVI) is mainly based on surgical practice. While waiting for the outcome of a number of ongoing trials comparing different antithrombotic regimes after TAVI, existing data indicate that, although OAC may potentially reduce the rate of ischaemic stroke as well as delay deterioration of the bioprosthetic valve, this ...

Sign in to read and download the full article

Forgot your password?
No account yet? Sign up for free!
Create my pcr account

Join us for free and access thousands of articles from EuroIntervention, as well as presentations, videos, cases from PCRonline.com

Read next article
Mitral valve regurgitation: a plea for transcatheter mitral valve replacement

Latest news